Celcuity to present updated Phase 3 VIKTORIA-1 gedatolisib data in HR+/HER2- advanced breast cancer at ESMO 2026
Bitget2026/10/05 12:04Celcuity flagged new disclosures on gedatolisib from its breast cancer and prostate cancer programs ahead of ESMO Congress 2026. Updated VIKTORIA-1 Phase 3 results will be presented in a late-breaking rapid oral session on Oct. 24, 2026. Data focus on additional subgroup findings in HR+/HER2- advanced breast cancer, targeting patients with PIK3CA-mutant tumors. Separate poster analyses will compare the gedatolisib triplet in PIK3CA wild-type disease against other post-CDK4/6 regimens. Another poster will present subgroup findings from a Phase 1b study of gedatolisib with darolutamide in metastatic castration-resistant prostate cancer. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celcuity Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050800PRIMZONEFULLFEED9839313) on October 05, 2026, and is solely responsible for the information contained therein.
- Celcuity flagged new disclosures on gedatolisib from its breast cancer and prostate cancer programs ahead of ESMO Congress 2026.
- Updated VIKTORIA-1 Phase 3 results will be presented in a late-breaking rapid oral session on Oct. 24, 2026.
- Data focus on additional subgroup findings in HR+/HER2- advanced breast cancer, targeting patients with PIK3CA-mutant tumors.
- Separate poster analyses will compare the gedatolisib triplet in PIK3CA wild-type disease against other post-CDK4/6 regimens.
- Another poster will present subgroup findings from a Phase 1b study of gedatolisib with darolutamide in metastatic castration-resistant prostate cancer.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Europe Becomes a Safe Haven Amid AI Turbulence! Citi Turns Bullish on European Stocks, Downgrades US Stocks: Low AI Exposure Seen as Key Advantage
Citigroup strategists have downgraded the rating of U.S. stocks and upgraded the rating of European stocks, following the recent market turbulence caused by upheaval in the artificial intelligence industry.
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Crypto prices
More
